BMRN BioMarin Pharmaceutical Inc. - Common Stock
Informazioni su BioMarin Pharmaceutical Inc. - Common Stock Panoramica della società da Wikipedia
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria (PKU).
Leggi di più
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I (MPS I), by manufacturing laronidase (Aldurazyme, commercialized by Genzyme Corporation). BioMarin was also the first company to provide therapeutics for phenylketonuria (PKU).
Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials.
History
BioMarin was founded in 1997 by Christopher Starr Ph.D. and Grant W. Denison Jr. with an investment of a $1.5 million from Glyko Biomedical and went public in 1999. Seed investors were amongst others MPM Bioventures, Grosvenor Fund and Florian Schönharting.
Business development
In 2002, BioMarin acquired Glyko Biomedical.
In 2009, BioMarin acquired Huxley Pharmaceuticals, Inc. (Huxley), which had rights to a proprietary form of 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate. In 2010, BioMarin was granted marketing approval by the European Commission for 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate for the treatment of the rare autoimmune disease Lambert–Eaton myasthenic syndrome (LEMS). BioMarin launched the product under the name Firdapse.
In 2010, BioMarin acquired LEAD Therapeutics, Inc. (LEAD), a small private drug discovery and early stage development company with key compound LT-673, an orally available poly (ADP-ribose) polymerase (PARP) inhibitor studied for the treatment of patients with rare, genetically defined cancers. This acquisition was followed by the purchase of ZyStor Therapeutics, Inc. (ZyStor), a privately held biotechnology company developing ERTs for the treatment of lysosomal storage disorders and its lead product candidate, ZC-701, a fusion of insulin-like growth factor 2 and alpha glucosidase (IGF2-GAA) in development for Pompe disease. At its R&D day in October 2010, BioMarin also announced a new program for a peptide therapeutic, vosoritide (BMN-111), for the treatment of achondroplasia.
In 2012, BioMarin acquired Zacharon Pharmaceuticals, a private biotechnology company based in San Diego focused on developing small molecules targeting pathways of glycan metabolism.
In 2014, BioMarin acquired a histone deacetylase inhibitor chemical library from Repligen for $2 million with the intention of advancing work toward therapies for Friedreich's ataxia and other neurological disorders.
In November 2014, the company agreed to the acquisition of Prosensa for up to $840 million; however, the range of treatments for Duchenne muscular dystrophy failed to attain FDA approval, and development ceased in May 2016.
In October 2019 it was revealed that the group will open an office in Dublin to support further growth through Europe, the Middle East and Asia.
In December 2025, BioMarin agreed to acquire Amicus Therapeutics for $4.8 billion.
Acquisition history
The following is an illustration of the company's major mergers and acquisitions and historical predecessors (this is not a comprehensive list):
Products
As of 2022, BioMarin has six products on the market, each of which is an orphan drug.
Tetrahydrobiopterin (branded as Kuvan) (sapropterin dihydrochloride), a small molecule drug for phenylketonuria, introduced in 2007 as the first medication-based intervention to treat phenylketonuria
Arylsulfatase B (branded as Naglazyme) (galsulfase), a recombinant protein therapeutic for Maroteaux–Lamy syndrome (also called mucopolysaccharidosis type VI)
Iduronidase (branded as Aldurazyme), a recombinant protein therapeutic for mucopolysaccharidosis I
Amifampridine (branded as Firdapse), a small molecule drug for Lambert–Eaton myasthenic syndrome (as of 2013 approved in the EU only)
Elosulfase alfa (branded as Vimizim), is the only enzyme replacement therapy to address the cause of Morquio A Syndrome (MPS IVA), which affects an estimated 3,000 patients in the developed world. The disease occurs as a result of a deficiency of activity in an enzyme involved in glycosaminoglycan (GAG) metabolism.
Cerliponase alfa (branded as Brineura), is an enzyme replacement treatment for Batten disease, which is a form of neuronal ceroid lipofuscinosis. It was approved in 2017.
Valoctocogene roxaparvovec (branded as Roctavian) is an adeno-associated viral vector for treatment of hemophilia A that aims to transfer a working copy of the Factor VIII gene into patients who lack one. It was approved in the EU in August 2022.
Biomarin is working to develop several new drugs.
Controversies
In 2010, BioMarin became involved in controversy surrounding 3,4-diaminopyridine (3,4-DAP). BioMarin markets a phosphate salt of 3,4-DAP under the name Firdapse. In 2010, BioMarin was granted exclusive licensing rights to Firdapse for 10 years. As a result, the price of a prescribed National Health Service treatment course has increased from $1,987 for the unlicensed drug to $69,970 for Firdapse. The company states that prior to its licensing, there was no guaranteed quality control of the product and no way of formally monitoring for uncommon side effects through the regulatory process.
In 2013, BioMarin Pharmaceuticals was at the center of a high-profile debate regarding expanded access of cancer patients to experimental drugs. On the advice of her doctor, Andrea Sloan, a patient with advanced ovarian cancer, requested that the company provide her with access to BMN 673, an unapproved PARP inhibitor drug candidate that had exhibited promising activity in a small Phase 1 clinical trial. The company declined, citing safety concerns. Ms. Sloan eventually received a similar drug candidate from a different company.
In 2015, there was another controversy over expanded access, concerning the supply of a drug on clinical trial to a German child who was suffering from a brain disorder but who was not part of the trial.
In April 2019, the BBC reported that patients who took part in a trial treatment for the drug Kuvan (sapropterin hydrochloride) were later denied access to it. The company was criticised by the NHS and Stephen Hammond MP for patient profiteering. The company commented the following in response: "BioMarin is disappointed that the NHS England has not recognised the value of treating PKU patients with Kuvan, despite more than a decade of positive patient outcomes across 26 countries in Europe, Russia and Turkey"
In June 2019, a Belgian court ordered BioMarin to continue supplying Vimizim to a young girl suffering from Morquio syndrome free of charge. BioMarin stopped providing free Vimizim at the beginning of the year after negotiations with Belgian health authorities regarding reimbursement of the product repeatedly failed. This caused the parents to start legal proceedings to force the company to keep providing the medicine free of charge. BioMarin was ordered in a preliminary injunction to keep doing so until a definitive judgment would be rendered, or until the medicine would be available on the Belgian market at a reasonable price.
Fonte: Wikipedia (Inglese), CC BY-SA 4.0 · Vedi su Wikipedia ↗
BMRN Snapshot del titolo Prezzo, capitalizzazione di mercato, P/E, EPS, ROE, debito/capitale proprio, intervallo 52 settimane
BMRN Grafico del prezzo delle azioni OHLCV giornaliero con indicatori tecnici — panoramica, zoom e personalizza la tua visualizzazione
Performance decennale Andamento di ricavi, utile netto, margini e EPS
Valutazione Rapporti P/E, P/S, P/B, EV/EBITDA — il titolo è costoso o economico?
Redditività Margini lordi, operativi e netti; ROE, ROA, ROIC
Salute finanziaria Debito, liquidità, solvibilità — solidità del bilancio
Crescita Crescita di ricavi, EPS e utile netto: YoY, CAGR 3Y, CAGR 5Y
Efficienza del Capitale Rotazione delle attività, rotazione delle scorte, rotazione dei crediti
BMRN Consenso degli analisti Opinioni degli analisti, sia rialziste che ribassiste, target price a 12 mesi, potenziale di rialzo
- Acquisto forte 10 30,3%
- Compra 16 48,5%
- Mantieni 7 21,2%
- Vendi 0 0,0%
- Vendita forte 0 0,0%
Target Price a 12 Mesi
26 analisti · 2026-08-21Cronologia utili EPS effettivo vs stima, surprise %, tasso di superamento, data prossimi utili
| Periodo | EPS Actual | EPS Stimato | Sorpresa |
|---|---|---|---|
| 30 Giugno 2026 | $0.73 | $0.70 | 0.03% |
| 31 Marzo 2026 | $0.54 | $0.77 | -0.23% |
| 31 Dicembre 2025 | $-0.24 | $0.64 | -0.88% |
| 30 Settembre 2025 | $-0.16 | $0.38 | -0.54% |
| 30 Giugno 2025 | $1.23 | $0.85 | 0.38% |
| 31 Marzo 2025 | $0.95 | $0.72 | 0.23% |
Confronto Peer (GICS sub-settore industriale) Metriche chiave rispetto ai pari del settore
| Ticker | Capitalizzazione di Mercato | P/E | Rev YoY | Margine Netto | ROE | Margine lordo |
|---|---|---|---|---|---|---|
| BMRN | $11.43B | 33.0 | 12.9% | 10.8% | 5.8% | — |
| UTHR | $21.27B | 17.5 | 10.6% | 41.9% | 18.7% | 87.9% |
| BBIO | $14.90B | -20.2 | 126.3% | -146.0% | 41.2% | — |
| NBIX | $14.20B | 30.4 | 21.4% | 16.7% | 16.1% | — |
| EXEL | $11.44B | 15.7 | 7.0% | 33.7% | 37.3% | — |
| ARWR | $4.68B | -3449.0 | 23258.2% | -0.20% | -0.50% | — |
| HALO | $7.93B | 26.3 | 37.5% | 22.7% | 166.1% | — |
| MDGL | $13.30B | -45.3 | 432.1% | -30.1% | -44.4% | — |
| CYTK | $7.81B | -9.7 | 376.6% | -891.6% | 152.7% | — |
| SMMT | $13.56B | -12.1 | — | — | -235.1% | — |
Fondamentali Completi Tutte le metriche per anno — conto economico, stato patrimoniale, rendiconto finanziario
Conto Economico 16
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.22B | $2.85B | $2.42B | $2.10B | $1.85B | $1.86B | $1.70B | $1.49B | $1.31B | $1.12B | $890M | $749M | |
| Cost of Revenue | $717M | $580M | $532M | $503M | $471M | $524M | $359M | $315M | $242M | $210M | $152M | $122M | |
| R&D Expense | $922M | $747M | $747M | $650M | $629M | $628M | $715M | $696M | $611M | $662M | $635M | $462M | |
| SG&A Expense | $1.15B | $1.01B | $892M | $823M | $759M | $738M | $681M | $604M | $554M | $477M | $402M | $302M | |
| Operating Expenses | $2.81B | $2.37B | $2.23B | $1.94B | $1.93B | $1.90B | $1.80B | $1.61B | $1.33B | $1.92B | $1.00B | $842M | |
| Operating Income | $409M | $484M | $186M | $161M | $-82M | $-43M | $-100M | $-124M | $-15M | $-803M | $-111M | $-93M | |
| Interest Expense | · | · | $17M | $16M | $15M | $29M | $23M | $44M | $43M | $39M | $38M | $37M | |
| Interest Income | $75M | $75M | $58M | $18M | $10M | $17M | $23M | $23M | $15M | $7M | $5M | $6M | |
| Pretax Income | $482M | $542M | $189M | $150M | $-75M | $-49M | $-95M | $-143M | $-36M | $-831M | $-155M | $-125M | |
| Income Tax | $134M | $115M | $21M | $8M | $-11M | $-903M | $-71M | $-65M | $81M | $-201M | $17M | $9M | |
| Net Income | $349M | $427M | $168M | $142M | $-64M | $854M | $-24M | $-77M | $-117M | $-630M | $-172M | $-134M | |
| EPS (Basic) | $1.82 | $2.25 | $0.89 | $0.76 | $-0.35 | $4.72 | $-0.13 | $-0.44 | $-0.67 | $-3.80 | $-1.07 | $-0.92 | |
| EPS (Diluted) | $1.80 | $2.21 | $0.87 | $0.75 | $-0.35 | $4.50 | $-0.13 | $-0.44 | $-0.67 | $-3.81 | $-1.07 | $-0.92 | |
| Shares (Basic) | 191,787,000 | 190,027,000 | 187,834,000 | 185,266,000 | 182,852,000 | 180,804,000 | 179,039,000 | 177,061,000 | 174,427,000 | 165,985,000 | 160,025,000 | 146,349,000 | |
| Shares (Diluted) | 197,394,000 | 196,708,000 | 191,595,000 | 188,963,000 | 182,852,000 | 191,678,000 | 179,039,000 | 177,268,000 | 174,427,000 | 166,219,000 | 160,025,000 | 146,349,000 | |
| EBITDA | $489M | $581M | $262M | $252M | $26M | $68M | $5M | $-28M | $73M | $-707M | $-64M | $-93M |
Stato Patrimoniale 28
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.31B | $943M | $755M | $725M | $587M | $649M | $437M | $494M | $598M | $408M | $397M | $875M | |
| Short-term Investments | · | · | · | · | · | · | · | · | $798M | $381M | $196M | $70M | |
| Receivables | $908M | $661M | $634M | $461M | $373M | $448M | $377M | $343M | $261M | $215M | $165M | $144M | |
| Inventory | $1.30B | $1.23B | $1.11B | $894M | $777M | $699M | $680M | $531M | $476M | $355M | $272M | $199M | |
| Prepaid Expense | · | · | · | · | · | · | · | · | · | · | $28M | $35M | |
| Other Current Assets | $186M | $202M | $141M | $105M | $110M | $130M | $131M | $98M | $74M | $62M | $60M | $109M | |
| Current Assets | $3.95B | $3.23B | $2.96B | $2.75B | $2.27B | $2.34B | $1.94B | $2.06B | $2.21B | $1.42B | $1.09B | $1.40B | |
| PP&E (Net) | $953M | $1.04B | $1.07B | $1.07B | $1.04B | $1.03B | $1.01B | $949M | $897M | $799M | $704M | $524M | |
| PP&E (Gross) | $2.03B | $1.93B | $1.93B | $1.88B | $1.76B | $1.67B | $1.56B | $1.42B | $1.30B | $1.14B | $983M | $752M | |
| Accum. Depreciation | $1.07B | $892M | $867M | $802M | $721M | $636M | $549M | $473M | $407M | $343M | $279M | $229M | |
| Goodwill | $196M | $196M | $196M | $196M | $196M | $196M | $197M | $197M | $197M | $197M | $197M | $54M | |
| Intangibles | $214M | $255M | $295M | $339M | $389M | $417M | $457M | $492M | $518M | $554M | $684M | $157M | |
| Other Non-current Assets | $277M | $251M | $172M | $176M | $152M | $142M | $122M | $37M | $30M | $33M | $409M | $55M | |
| Total Assets | $7.59B | $6.99B | $6.84B | $6.38B | $6.00B | $5.85B | $4.69B | $4.43B | $4.63B | $4.02B | $3.73B | $2.48B | |
| Accounts Payable | $759M | $607M | $683M | $573M | $498M | $493M | $571M | $437M | $402M | $371M | $393M | $232M | |
| Accrued Liabilities | · | · | · | · | · | · | · | · | · | · | · | $98M | |
| Current Liabilities | $759M | $607M | $1.18B | $589M | $546M | $493M | $933M | $523M | $817M | $439M | $445M | $236M | |
| Capital Leases | $37M | $31M | $38M | $26M | $32M | $40M | $44M | · | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | $0 | $144M | · | |
| Other Non-current Liabilities | $151M | $129M | $120M | $100M | $98M | $114M | $98M | $59M | $59M | $42M | $45M | $30M | |
| Total Liabilities | $1.51B | $1.33B | $1.89B | $1.77B | $1.74B | $1.74B | $1.57B | $1.46B | $1.82B | $1.26B | $1.33B | $947M | |
| Long-term Debt | $597M | · | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $192.0K | $191.0K | $189.0K | $186.0K | $184.0K | $182.0K | $180.0K | $178.0K | $176.0K | $173.0K | $162.0K | $149.0K | |
| Retained Earnings | $154M | $-195M | $-622M | $-789M | $-931M | $-862M | $-1.72B | $-1.69B | $-1.64B | $-1.52B | $-1.02B | $-850M | |
| AOCI | $-13M | $62M | $-29M | $-4M | $14M | $-16M | $20M | $5M | $-23M | $13M | $21M | $27M | |
| Stockholders' Equity | $6.09B | $5.66B | $4.95B | $4.60B | $4.27B | $4.10B | $3.12B | $2.97B | $2.81B | $2.77B | $2.40B | $1.53B | |
| Liabilities + Equity | $7.59B | $6.99B | $6.84B | $6.38B | $6.00B | $5.85B | $4.69B | $4.43B | $4.63B | $4.02B | $3.73B | $2.48B | |
| Shares Outstanding | 192,300,101 | 190,761,000 | 188,598,000 | 186,251,000 | 183,913,000 | 181,741,000 | 179,838,000 | 178,252,954 | 175,843,749 | 172,647,588 | 161,526,044 | 149,093,647 |
Flusso di cassa 16
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $80M | $96M | $104M | $102M | $108M | $105M | $105M | $96M | $88M | $97M | $47M | $46M | |
| Stock-based Comp | $181M | $202M | $207M | $196M | $197M | $190M | $160M | $149M | $140M | $135M | $112M | $86M | |
| Deferred Tax | $49M | $56M | $-45M | $-52M | $-16M | $-890M | $-83M | $-68M | $44M | $-228M | $-77M | $-26M | |
| Amort. of Intangibles | $19M | $43M | $62M | $67M | · | · | · | · | · | · | · | $10M | |
| Other Non-cash | $169M | $-208M | $-275M | $-212M | $79M | $-180M | $-110M | $-79M | $-164M | $399M | $-132M | · | |
| Operating Cash Flow | $828M | $573M | $159M | $176M | $305M | $85M | $48M | $20M | $-9M | $-228M | $-219M | $-70M | |
| CapEx | $103M | $85M | $97M | $121M | $96M | $114M | $145M | $145M | $199M | $148M | $228M | $117M | |
| Investing Cash Flow | $-414M | $136M | $-111M | $-20M | $-366M | $-54M | $-31M | $264M | $-305M | $-484M | · | · | |
| Stock Issued | · | · | · | · | · | · | · | $0 | $0 | $713M | $888M | $117M | |
| Stock Repurchased | · | · | · | $0 | $0 | $50M | $0 | $0 | · | · | · | · | |
| Net Stock Activity | · | · | · | $0 | $0 | $-50M | · | $0 | $0 | $713M | $888M | $117M | |
| Financing Cash Flow | $-42M | $-526M | $-19M | $-19M | $-48.0K | $181M | $-75M | $-388M | $507M | $727M | · | · | |
| Net Change in Cash | $369M | $188M | $31M | $137M | $-62M | $212M | $-57M | $-104M | $190M | $11M | $-478M | $307M | |
| Taxes Paid | $96M | · | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $725M | $487M | $63M | $55M | $209M | $-29M | $-97M | $-124M | $-208M | $-376M | $-449M | $-192M | |
| Levered FCF | · | · | $47M | $40M | $196M | $566M | $-103M | $-148M | $-347M | $-406M | $-492M | $-232M |
Redditività 7
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 12.7% | 17.0% | 6.5% | 7.1% | -4.5% | -2.0% | -5.9% | -8.3% | -1.1% | -71.9% | -12.4% | -12.4% | |
| Net Margin | 10.8% | 15.0% | 6.9% | 6.8% | -3.5% | 46.2% | -1.4% | -5.2% | -8.9% | -56.4% | -19.3% | -17.8% | |
| Pretax Margin | 15.0% | 19.0% | 7.8% | 7.1% | -4.1% | -2.3% | -5.6% | -9.6% | -2.7% | -74.4% | -17.4% | -16.6% | |
| EBITDA Margin | 15.2% | 20.3% | 10.8% | 12.0% | 1.4% | 3.7% | 0.28% | -1.9% | 5.6% | -63.3% | -7.1% | -12.4% | |
| ROA | 4.8% | 6.2% | 2.5% | 2.3% | -1.1% | 16.3% | -0.52% | -1.7% | -2.7% | -16.3% | -5.5% | -5.7% | |
| ROE | 5.8% | 7.7% | 3.4% | 3.1% | -1.5% | 21.1% | -0.77% | -2.6% | -4.2% | -24.4% | -8.8% | -9.3% | |
| ROIC | 4.9% | 6.7% | 2.8% | 3.1% | -1.6% | 18.2% | -0.81% | -2.2% | -1.7% | -22.0% | -5.1% | -6.5% |
Liquidità e Solvibilità 3
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.2 | 5.3 | 2.5 | 4.7 | 4.2 | 4.8 | 2.1 | 3.9 | 2.7 | 3.2 | 2.4 | 6.0 | |
| Quick Ratio | 2.9 | 2.6 | 1.2 | 2.0 | 1.8 | 2.2 | 0.9 | 1.6 | 2.0 | 2.3 | 1.7 | 4.6 | |
| Interest Coverage | · | · | 9.1 | 9.4 | -5.4 | -1.3 | -4.3 | -2.8 | -0.3 | -20.3 | -2.9 | -2.5 |
Efficienza 3
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.4 | 0.4 | 0.3 | 0.3 | 0.4 | 0.4 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | |
| Inventory Turnover | 0.6 | 0.5 | 0.5 | 0.6 | 0.6 | 0.8 | 0.6 | 0.6 | 0.6 | 0.7 | 0.6 | 0.7 | |
| Receivables Turnover | 4.1 | 4.4 | 4.4 | 5.0 | 4.5 | 4.5 | 4.7 | 4.9 | 5.5 | 5.9 | 5.8 | 5.7 |
Tassi di Crescita 9
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 12.9% | 18.0% | 15.4% | 13.5% | -0.76% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 15.4% | 15.6% | 9.2% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 11.6% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | -18.6% | 154.0% | 16.0% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 33.9% | · | -42.2% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | -16.7% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | -18.3% | 154.6% | 18.4% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 35.1% | · | -41.9% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | -16.4% | · | · | · | · | · | · | · | · | · | · | · |
Valutazione (TTM) 10
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $3.22B | $2.85B | $2.42B | $2.10B | $1.85B | $1.86B | $1.70B | $1.49B | $1.31B | $1.12B | $890M | $749M | |
| Net Income TTM | $349M | $427M | $168M | $142M | $-64M | $854M | $-24M | $-77M | $-117M | $-630M | $-172M | $-134M | |
| Market Cap | $11.43B | $12.54B | $18.18B | $19.28B | $16.25B | $15.94B | $15.21B | $15.18B | $15.68B | $14.30B | $16.92B | $13.48B | |
| P/E | 33.0 | 29.7 | 110.8 | 138.0 | -252.4 | 19.5 | -650.4 | -193.5 | -133.1 | -21.7 | -97.9 | -98.3 | |
| P/S | 3.5 | 4.4 | 7.5 | 9.2 | 8.8 | 8.6 | 8.9 | 10.2 | 11.9 | 12.8 | 19.0 | 18.0 | |
| P/B | 1.9 | 2.2 | 3.7 | 4.2 | 3.8 | 3.9 | 4.9 | 5.1 | 5.6 | 5.2 | 7.0 | 8.8 | |
| P / Tangible Book | 2.0 | 2.4 | 4.1 | 4.7 | 4.4 | 4.6 | · | · | · | · | · | · | |
| P / Cash Flow | 13.8 | 21.9 | 114.2 | 109.6 | 53.4 | 186.7 | 315.1 | 751.1 | -1790.6 | -62.8 | -76.3 | -183.3 | |
| P / FCF | 15.8 | 25.7 | 290.6 | 350.8 | 77.8 | -550.6 | -157.1 | -122.0 | -75.4 | -38.0 | -37.7 | -70.1 | |
| Earnings Yield | 3.0% | 3.4% | 0.90% | 0.72% | -0.40% | 5.1% | -0.15% | -0.52% | -0.75% | -4.6% | -1.0% | -1.0% |
Conto Economico 16
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $990M | $766M | $875M | $776M | $825M | $745M | $747M | $746M | $712M | $649M | $646M | $581M | $595M | $596M | $538M | $505M | |
| Cost of Revenue | $203M | $195M | $276M | $140M | $150M | $152M | $136M | $188M | $130M | $125M | $138M | $128M | $131M | $135M | $147M | $116M | |
| R&D Expense | $207M | $179M | $192M | $409M | $161M | $159M | $174M | $185M | $184M | $205M | $206M | $191M | $177M | $172M | $173M | $158M | |
| SG&A Expense | $396M | $258M | $446M | $268M | $232M | $206M | $267M | $253M | $263M | $226M | $260M | $216M | $206M | $211M | $215M | $217M | |
| Operating Expenses | $879M | $637M | $919M | $823M | $549M | $521M | $586M | $632M | $592M | $560M | $619M | $551M | $530M | $534M | $551M | $508M | |
| Operating Income | $111M | $130M | $-45M | $-47M | $277M | $224M | $161M | $114M | $120M | $88M | $27M | $31M | $66M | $62M | $-13M | $-2M | |
| Interest Expense | $61M | $10M | · | · | $2M | $2M | · | · | · | $4M | · | $4M | $4M | $4M | · | $5M | |
| Interest Income | $10M | $23M | $19M | $18M | $19M | $19M | $18M | $18M | $20M | $19M | $18M | $16M | $13M | $12M | $9M | $5M | |
| Pretax Income | $61M | $141M | $-27M | $-26M | $298M | $238M | $170M | $134M | $132M | $106M | $19M | $42M | $71M | $57M | $-18M | $-2M | |
| Income Tax | $17M | $36M | $19M | $4M | $57M | $52M | $45M | $28M | $25M | $17M | $-1M | $1M | $15M | $6M | $-17M | $5M | |
| Net Income | $45M | $106M | $-47M | $-31M | $241M | $186M | $125M | $106M | $107M | $89M | $20M | $40M | $56M | $51M | $-249.0K | $-7M | |
| EPS (Basic) | $0.23 | $0.55 | $-0.24 | $-0.16 | $1.25 | $0.97 | $0.66 | $0.56 | $0.56 | $0.47 | $0.11 | $0.21 | $0.30 | $0.27 | $-0.01 | $-0.04 | |
| EPS (Diluted) | $0.23 | $0.54 | $-0.22 | $-0.16 | $1.23 | $0.95 | $0.65 | $0.55 | $0.55 | $0.46 | $0.10 | $0.21 | $0.29 | $0.27 | $0.01 | $-0.04 | |
| Shares (Basic) | 193,423,000 | 192,497,000 | -383,119,000 | 192,032,000 | 191,907,000 | 190,967,000 | -379,382,000 | 190,429,000 | 190,114,000 | 188,866,000 | -375,000,000 | 188,219,000 | 187,948,000 | 186,667,000 | -369,575,000 | 185,597,000 | |
| Shares (Diluted) | 194,467,000 | 197,671,000 | -388,203,000 | 192,032,000 | 197,091,000 | 196,474,000 | -400,206,000 | 197,147,000 | 200,505,000 | 199,262,000 | -388,939,000 | 191,173,000 | 194,998,000 | 194,363,000 | -378,968,000 | 185,597,000 | |
| EBITDA | $111M | $146M | · | $-47M | $277M | $246M | · | $114M | $120M | $116M | · | $26M | $59M | $86M | · | $-2M |
Stato Patrimoniale 25
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $874M | $2.22B | $1.31B | $1.25B | $1.21B | $1.05B | $943M | $675M | $972M | $747M | · | $785M | $694M | $580M | · | $762M | |
| Receivables | $1.06B | $904M | $908M | $790M | $856M | $739M | $661M | $778M | $691M | $637M | · | $572M | $610M | $598M | · | $420M | |
| Inventory | $1.78B | $1.27B | $1.30B | $1.38B | $1.34B | $1.27B | $1.23B | $1.18B | $1.18B | $1.14B | · | $1.03B | $976M | $919M | · | $839M | |
| Other Current Assets | $254M | $206M | $186M | $204M | $177M | $182M | $202M | $169M | $160M | $163M | · | $225M | $193M | $173M | · | $150M | |
| Current Assets | $3.97B | $4.61B | $3.95B | $3.85B | $3.81B | $3.47B | $3.23B | $3.06B | $3.26B | $2.99B | · | $2.96B | $2.95B | $2.84B | · | $2.68B | |
| PP&E (Net) | $990M | $958M | $953M | $1.04B | $1.03B | $1.03B | $1.04B | $1.05B | $1.05B | $1.06B | · | $1.07B | $1.07B | $1.07B | · | $1.05B | |
| PP&E (Gross) | $2.10B | $2.05B | $2.03B | $1.99B | $1.96B | $1.94B | $1.93B | $1.91B | $1.96B | $1.95B | · | $1.92B | $1.90B | $1.88B | · | $1.83B | |
| Accum. Depreciation | $1.11B | $1.09B | $1.07B | $950M | $931M | $908M | $892M | $869M | $910M | $888M | · | $851M | $829M | $807M | · | $782M | |
| Goodwill | $656M | $196M | $196M | $196M | $196M | $196M | $196M | $196M | $196M | $196M | · | $196M | $196M | $196M | · | $196M | |
| Intangibles | $4.88B | $205M | $214M | $233M | $240M | $247M | $255M | $261M | $266M | $280M | · | $302M | $310M | $326M | · | $354M | |
| Other Non-current Assets | $338M | $276M | $277M | $271M | $249M | $236M | $251M | $199M | $191M | $185M | · | $165M | $144M | $150M | · | $152M | |
| Total Assets | $11.72B | $8.59B | $7.59B | $7.61B | $7.46B | $7.15B | $6.99B | $6.85B | $7.07B | $6.87B | · | $6.76B | $6.56B | $6.43B | · | $6.26B | |
| Accounts Payable | $1.01B | $793M | $759M | $798M | $684M | $628M | $607M | $716M | $572M | $594M | · | $670M | $597M | $598M | · | $493M | |
| Current Liabilities | $1.66B | $793M | $759M | $798M | $684M | $628M | $607M | $716M | $1.07B | $1.09B | · | $1.16B | $597M | $598M | · | $521M | |
| Capital Leases | · | · | $37M | · | · | · | $31M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $210M | $155M | $151M | $163M | $149M | $130M | $129M | $128M | $119M | $117M | · | $105M | $98M | $92M | · | $92M | |
| Total Liabilities | $5.40B | $2.38B | $1.51B | $1.56B | $1.43B | $1.35B | $1.33B | $1.44B | $1.78B | $1.80B | · | $1.86B | $1.78B | $1.77B | · | $1.70B | |
| Long-term Debt | $4.19B | $1.43B | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Total Debt | $4.19B | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $194.0K | $193.0K | $192.0K | $192.0K | $192.0K | $192.0K | $191.0K | $191.0K | $190.0K | $190.0K | · | $188.0K | $188.0K | $188.0K | · | $186.0K | |
| Retained Earnings | $304M | $260M | $154M | $201M | $232M | $-9M | $-195M | $-320M | $-426M | $-533M | · | $-642M | $-682M | $-738M | · | $-789M | |
| AOCI | $-9M | $-4M | $-13M | $-34M | $-45M | $19M | $62M | $5M | $27M | $-1M | · | $6M | $-19M | $-11M | · | $31M | |
| Stockholders' Equity | $6.32B | $6.21B | $6.09B | $6.06B | $6.03B | $5.79B | $5.66B | $5.41B | $5.29B | $5.07B | $4.95B | $4.90B | $4.78B | $4.66B | $4.60B | $4.57B | |
| Liabilities + Equity | $11.72B | $8.59B | $7.59B | $7.61B | $7.46B | $7.15B | $6.99B | $6.85B | $7.07B | $6.87B | · | $6.76B | $6.56B | $6.43B | · | $6.26B | |
| Shares Outstanding | 193,535,556 | 193,268,870 | 192,300,101 | 192,098,751 | 192,001,650 | 191,755,802 | 190,761,349 | 190,553,918 | 190,355,517 | 189,776,577 | 188,598,000 | 188,339,482 | 188,151,695 | 187,601,106 | 186,251,000 | 185,824,253 |
Flusso di cassa 13
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $98M | $16M | $20M | $18M | $19M | $22M | $24M | $19M | $26M | $27M | $27M | $26M | $25M | $26M | $25M | $25M | |
| Stock-based Comp | $76M | $43M | $47M | $49M | $48M | $38M | $52M | $43M | $48M | $58M | $55M | $48M | $50M | $54M | $47M | $55M | |
| Deferred Tax | $-7M | $9M | $613.0K | $-14M | $33M | $28M | $42M | $12M | $1M | $285.0K | $-25M | $-15M | $1M | $-6M | $-51M | $-4M | |
| Amort. of Intangibles | $73M | $4M | $5M | $5M | $5M | $5M | $10M | $5M | $14M | $14M | $15M | $16M | $16M | $16M | · | · | |
| Restructuring | $56M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | $46M | · | · | · | $-99M | · | · | · | $-128M | · | · | · | $-199M | · | · | |
| Operating Cash Flow | $168M | $221M | $100M | $369M | $185M | $174M | $186M | $221M | $119M | $47M | $27M | $136M | $70M | $-74M | $7M | $158M | |
| CapEx | $29M | $21M | $41M | $28M | $17M | $17M | $20M | $18M | $21M | $26M | $29M | $22M | $22M | $24M | $36M | $29M | |
| Investing Cash Flow | $-5.10B | $726M | $-42M | $-331M | $-13M | $-28M | $76M | $-16M | $90M | $-14M | $-65M | $-46M | $30M | $-30M | $-55M | $-23M | |
| Financing Cash Flow | $2.74B | $813M | $3M | $-2M | $-5M | $-39M | $3M | $-499M | $13M | $-43M | $11M | $-788.0K | $12M | $-41M | $11M | $8M | |
| Net Change in Cash | $-2.20B | $1.76B | $62M | $36M | $165M | $106M | $267M | $-297M | $225M | $-8M | $-30M | $91M | $114M | $-144M | $-37M | $142M | |
| Free Cash Flow | · | $200M | · | · | · | $158M | · | · | · | $21M | · | · | · | $-98M | · | · | |
| Levered FCF | · | $193M | · | · | · | · | · | · | · | $18M | · | · | · | $-102M | · | · |
Redditività 7
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 11.2% | 16.9% | · | -6.0% | 33.6% | 30.0% | · | 15.3% | 16.9% | 13.6% | · | 4.4% | 9.9% | 10.0% | · | -0.48% | |
| Net Margin | 4.5% | 13.8% | · | -4.0% | 29.1% | 24.9% | · | 14.2% | 15.0% | 13.7% | · | 7.0% | 9.4% | 8.5% | · | -1.3% | |
| Pretax Margin | 6.2% | 18.4% | · | -3.4% | 36.1% | 31.9% | · | 18.0% | 18.6% | 16.3% | · | 7.2% | 11.9% | 9.5% | · | -0.38% | |
| EBITDA Margin | 11.2% | 19.1% | · | -6.0% | 33.6% | 33.0% | · | 15.3% | 16.9% | 17.8% | · | 4.4% | 9.9% | 14.4% | · | -0.48% | |
| ROA | 0.47% | 1.3% | · | -0.43% | 3.3% | 2.6% | · | 1.6% | 1.6% | 1.3% | · | 0.62% | 0.88% | 0.81% | · | -0.11% | |
| ROE | 0.72% | 1.8% | · | -0.54% | 4.2% | 3.4% | · | 2.1% | 2.1% | 1.8% | · | 0.85% | 1.2% | 1.1% | · | -0.15% | |
| ROIC | 0.77% | 1.6% | · | -0.90% | 3.7% | 3.0% | · | 1.7% | 1.8% | 1.5% | · | 0.51% | 0.97% | 1.1% | · | -0.18% |
Liquidità e Solvibilità 5
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.4 | 5.8 | · | 4.8 | 5.6 | 5.5 | · | 4.3 | 3.1 | 2.7 | · | 2.5 | 4.9 | 4.8 | · | 5.1 | |
| Quick Ratio | 1.2 | 3.9 | · | 2.6 | 3.0 | 2.8 | · | 2.0 | 1.6 | 1.3 | · | 1.2 | 2.2 | 2.0 | · | 2.3 | |
| Debt / Equity | 0.7 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| LT Debt / Equity | 0.6 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Interest Coverage | 1.8 | 13.5 | · | · | · | · | · | · | · | 24.9 | · | 6.8 | 15.7 | 16.0 | · | -0.5 |
Efficienza 3
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Inventory Turnover | 0.1 | 0.2 | · | 0.1 | 0.1 | 0.1 | · | 0.2 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 1.0 | 0.9 | · | 1.0 | 1.1 | 1.1 | · | 1.1 | 1.1 | 1.1 | · | 1.2 | 1.1 | 1.2 | · | 1.3 |
Valutazione (TTM) 13
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $3.36B | $3.11B | · | $3.09B | $3.03B | $2.85B | · | $2.69B | $2.54B | $2.42B | · | $2.28B | $2.23B | $2.15B | · | $1.97B | |
| Net Income TTM | $360M | $501M | · | $502M | $639M | $488M | · | $342M | $292M | $236M | · | $141M | $128M | $193M | · | $105M | |
| Market Cap | $11.07B | $10.92B | · | $10.40B | $10.55B | $13.56B | · | $13.39B | $15.67B | $16.58B | · | $16.66B | $16.31B | $18.24B | · | $15.75B | |
| Enterprise Value | $14.39B | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/E | 31.1 | 22.1 | · | 21.1 | 16.8 | 28.2 | · | 39.7 | 54.5 | 71.0 | · | 121.2 | 129.4 | 96.3 | · | 157.0 | |
| P/S | 3.3 | 3.5 | · | 3.4 | 3.5 | 4.8 | · | 5.0 | 6.2 | 6.8 | · | 7.3 | 7.3 | 8.5 | · | 8.0 | |
| P/B | 1.8 | 1.8 | · | 1.7 | 1.8 | 2.3 | · | 2.5 | 3.0 | 3.3 | · | 3.4 | 3.4 | 3.9 | · | 3.4 | |
| P / Tangible Book | 14.1 | 1.9 | · | 1.8 | 1.9 | 2.5 | · | 2.7 | 3.2 | 3.6 | · | 3.8 | 3.8 | 4.4 | · | 3.9 | |
| P / Cash Flow | · | 49.5 | · | · | · | 77.7 | · | · | · | 352.9 | · | · | · | -246.7 | · | · | |
| P / FCF | · | 54.7 | · | · | · | 86.0 | · | · | · | 794.3 | · | · | · | -185.4 | · | · | |
| EV / EBITDA | 129.7 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| EV / Revenue | 4.3 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | 3.2% | 4.5% | · | 4.8% | 6.0% | 3.5% | · | 2.5% | 1.8% | 1.4% | · | 0.83% | 0.77% | 1.0% | · | 0.64% |
Bilanci Conto economico, stato patrimoniale, flusso di cassa — annuale, ultimi 5 anni
Conto Economico
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ricavi | $3.22B | $2.85B | $2.42B | $2.10B | $1.85B |
| Margine Operativo % | 12.7% | 17.0% | 6.5% | 7.1% | -4.5% |
| Utile netto | $349M | $427M | $168M | $142M | $-64M |
| EPS Diluito | $1.80 | $2.21 | $0.87 | $0.75 | $-0.35 |
Stato Patrimoniale
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Rapporto corrente | 5.2 | 5.3 | 2.5 | 4.7 | 4.2 |
| Quick Ratio | 2.9 | 2.6 | 1.2 | 2.0 | 1.8 |
Flusso di cassa
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Flusso di cassa libero | $725M | $487M | $63M | $55M | $209M |
Ultime notizie Notizie recenti che menzionano questa società
- Biomarin Pharmaceutical (BMRN): Most Undervalued Stocks to Buy and Hold for 2 Years
- BioMarin Pharmaceutical Inc. (BMRN) è una delle migliori azioni a basso costo da acquistare con il maggiore potenziale di rialzo?
- BioMarin nomina Ian Clark come presidente del consiglio di amministrazione
- BioMarin Pharmaceutical (BMRN) comunica risultati positivi dai trial in corso di VOXZOGO
Segnali di trading Segnali recenti di acquisto/vendita con prezzo di entrata e rapporto rischio/rendimento
Le Mie Metriche La tua watchlist personale — righe selezionate da Fondamentali Completi
Scegli le metriche che contano per te — fai clic sul ➕ accanto a qualsiasi riga nei Fondamentali Completi sopra.
La tua selezione è salvata e ti segue su tutti i ticker.
Proprietari istituzionali (13F) 616 filer · $8.6B totale · Aggiornato al 30 Giugno 2026
Istituzioni che segnalano il possesso di questo titolo nel loro Modulo SEC 13F trimestrale. Solo posizioni lunghe; un singolo depositante può apparire due volte per diverse gambe di opzioni. Grandi posizioni put/call contrapposte riflettono tipicamente market-making o inventario coperto, non convinzione direzionale.
| Nuove posizioni | Posizioni chiuse | Aumentato | Diminuito | Variazione netta delle azioni |
|---|---|---|---|---|
| 89 (-12 vs trimestre precedente) | 75 (+10 vs trimestre precedente) | 195 (-13 vs trimestre precedente) | 205 (+40 vs trimestre precedente) | +10.3M |
Confrontato con Q1 2026. Le dichiarazioni SEC Form 13F sono dovute entro 45 giorni dalla fine del trimestre più un breve margine per i dichiaranti in ritardo — i trimestri ancora all'interno di questa finestra vengono saltati a favore della coppia più recente completamente riportata.
| Istituzione | Valore | Azioni | % di 13F tracciati | Tipo |
|---|---|---|---|---|
| Dodge & Cox | $849.426.895 | 14.844.930 | 9,87% | Azioni |
| PRIMECAP MANAGEMENT CO/CA/ | $811.962.329 | 14.190.183 | 9,44% | Azioni |
| VANGUARD CAPITAL MANAGEMENT LLC | $500.310.680 | 8.743.633 | 5,82% | Azioni |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $494.877.355 | 8.648.678 | 5,75% | Azioni |
| NORGES BANK | $469.659.128 | 8.207.954 | 5,46% | Azioni |
| STATE STREET CORP | $446.370.874 | 7.800.959 | 5,19% | Azioni |
| VIKING GLOBAL INVESTORS LP | $435.819.735 | 7.616.563 | 5,07% | Azioni |
| Vestal Point Capital, LP | $344.750.500 | 6.025.000 | 4,01% | Azioni |
| DIMENSIONAL FUND ADVISORS LP | $216.743.752 | 3.787.902 | 2,52% | Azioni |
| Capital Research Global Investors | $200.521.024 | 3.504.387 | 2,33% | Azioni |
| FMR LLC | $196.878.227 | 3.440.724 | 2,29% | Azioni |
| Deep Track Capital, LP | $189.254.063 | 3.307.481 | 2,20% | Azioni |
| GEODE CAPITAL MANAGEMENT, LLC | $180.073.856 | 3.146.120 | 2,09% | Azioni |
| MILLENNIUM MANAGEMENT LLC | $118.549.312 | 2.071.816 | 1,38% | Azioni |
| Assenagon Asset Management S.A. | $100.826.561 | 1.762.086 | 1,17% | Azioni |
| FIRST TRUST ADVISORS LP | $91.910.897 | 1.606.273 | 1,07% | Azioni |
| Jones Hill Capital LP | $81.915.580 | 1.431.590 | 0,95% | Azioni |
| DEERFIELD MANAGEMENT COMPANY, L.P. | $76.264.876 | 1.332.836 | 0,89% | Azioni |
| Swedbank AB | $75.232.112 | 1.314.787 | 0,87% | Azioni |
| DNB Asset Management AS | $72.566.061 | 1.268.194 | 0,84% | Azioni |
| Caisse de depot et placement du Quebec | $70.749.440 | 1.236.446 | 0,82% | Azioni |
| VANGUARD FIDUCIARY TRUST CO | $70.030.356 | 1.223.879 | 0,81% | Azioni |
| AMERIPRISE FINANCIAL INC | $65.664.916 | 1.147.544 | 0,76% | Azioni |
| CITADEL ADVISORS LLC | $64.224.186 | 1.122.408 | 0,75% | Azioni |
| Balyasny Asset Management L.P. | $60.344.956 | 1.054.613 | 0,70% | Azioni |
| ARGA Investment Management, LP | $59.474.983 | 1.039.409 | 0,69% | Azioni |
| GOLDMAN SACHS GROUP INC | $56.321.074 | 984.290 | 0,65% | Azioni |
| Brandywine Global Investment Management, LLC | $56.211.687 | 945.847 | 0,65% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $54.484.884 | 952.200 | 0,63% | Opzione Call |
| MACKENZIE FINANCIAL CORP | $53.321.258 | 931.864 | 0,62% | Azioni |
| FRANKLIN RESOURCES INC | $47.889.936 | 836.944 | 0,56% | Azioni |
| Hudson Bay Capital Management LP | $47.206.500 | 825.000 | 0,55% | Azioni |
| FORT WASHINGTON INVESTMENT ADVISORS INC /OH/ | $40.949.264 | 715.646 | 0,48% | Azioni |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $39.869.980 | 696.784 | 0,46% | Azioni |
| EDMOND DE ROTHSCHILD HOLDING S.A. | $39.311.857 | 687.030 | 0,46% | Azioni |
| Palo Alto Investors LP | $39.068.500 | 682.777 | 0,45% | Azioni |
| Defilade Capital Management, L.P. | $39.024.326 | 682.005 | 0,45% | Azioni |
| Qube Research & Technologies Ltd | $38.270.739 | 668.835 | 0,44% | Azioni |
| Eagle Health Investments LP | $35.743.961 | 624.676 | 0,42% | Azioni |
| VICTORY CAPITAL MANAGEMENT INC | $34.419.661 | 601.532 | 0,40% | Azioni |
| BOONE CAPITAL MANAGEMENT LLC | $33.371.791 | 583.219 | 0,39% | Azioni |
| Camber Capital Management LP | $32.982.000 | 600.000 | 0,38% | Azioni |
| River Road Asset Management, LLC | $31.069.888 | 542.990 | 0,36% | Azioni |
| RHUMBLINE ADVISERS | $29.570.438 | 516.786 | 0,34% | Azioni |
| Trails Edge Capital Partners, LP | $29.296.640 | 512.000 | 0,34% | Azioni |
| BNP PARIBAS FINANCIAL MARKETS | $28.048.615 | 490.189 | 0,33% | Azioni |
| Jefferies Financial Group Inc. | $26.679.283 | 466.258 | 0,31% | Azioni |
| LOOMIS SAYLES & CO L P | $25.986.177 | 454.145 | 0,30% | Azioni |
| RENAISSANCE TECHNOLOGIES LLC | $25.856.059 | 451.871 | 0,30% | Azioni |
| HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC | $25.588.784 | 447.200 | 0,30% | Azioni |
| California Public Employees Retirement System | $25.124.959 | 439.094 | 0,29% | Azioni |
| Rockefeller Capital Management L.P. | $24.797.775 | 433.376 | 0,29% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $24.038.122 | 420.100 | 0,28% | Opzione Put |
| SEB Asset Management AB | $23.583.178 | 412.150 | 0,27% | Azioni |
| Robeco Institutional Asset Management B.V. | $23.358.064 | 408.215 | 0,27% | Azioni |
| Pictet Asset Management Holding SA | $22.789.414 | 395.382 | 0,26% | Azioni |
| BlackRock, Inc. | $22.697.229 | 396.666 | 0,26% | Azioni |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $22.513.495 | 393.455 | 0,26% | Azioni |
| PRUDENTIAL FINANCIAL INC | $22.325.585 | 390.171 | 0,26% | Azioni |
| Soleus Capital Management, L.P. | $21.490.230 | 375.572 | 0,25% | Azioni |
| Freestone Grove Partners LP | $20.839.181 | 364.194 | 0,24% | Azioni |
| Sofinnova Investments, Inc. | $20.517.261 | 358.568 | 0,24% | Azioni |
| Swiss National Bank | $20.427.540 | 357.000 | 0,24% | Azioni |
| LAZARD ASSET MANAGEMENT LLC | $20.049.716 | 350.397 | 0,23% | Azioni |
| BANK OF AMERICA CORP /DE/ | $19.371.831 | 338.550 | 0,23% | Azioni |
| EASTERLY INVESTMENT PARTNERS LLC | $18.847.524 | 329.387 | 0,22% | Azioni |
| SPHERA FUNDS MANAGEMENT LTD. | $18.799.631 | 328.550 | 0,22% | Azioni |
| DIADEMA PARTNERS LP | $17.901.048 | 312.846 | 0,21% | Azioni |
| SECTOR GAMMA AS | $16.875.208 | 294.918 | 0,20% | Azioni |
| Rhenman & Partners Asset Management AB | $16.622.410 | 290.500 | 0,19% | Azioni |
| Walleye Capital LLC | $16.492.692 | 288.233 | 0,19% | Azioni |
| SYSTEMATIC FINANCIAL MANAGEMENT LP | $16.114.296 | 281.620 | 0,19% | Azioni |
| ALLIANCEBERNSTEIN L.P. | $16.009.266 | 283.400 | 0,19% | Azioni |
| Bridgewater Associates, LP | $15.730.407 | 274.911 | 0,18% | Azioni |
| Susquehanna Portfolio Strategies, LLC | $15.653.218 | 273.562 | 0,18% | Azioni |
| Redmile Group, LLC | $15.172.970 | 265.169 | 0,18% | Azioni |
| Amundi | $14.864.727 | 259.782 | 0,17% | Azioni |
| Eversept Partners, LP | $14.282.513 | 249.607 | 0,17% | Azioni |
| Distillate Capital Partners LLC | $14.242.974 | 248.916 | 0,17% | Azioni |
| RICE HALL JAMES & ASSOCIATES, LLC | $14.203.377 | 248.224 | 0,17% | Azioni |
| CAPITAL FUND MANAGEMENT S.A. | $13.470.789 | 235.421 | 0,16% | Azioni |
| CITADEL ADVISORS LLC | $13.189.210 | 230.500 | 0,15% | Opzione Call |
| CANADA PENSION PLAN INVESTMENT BOARD | $12.868.778 | 224.900 | 0,15% | Azioni |
| M&G PLC | $12.317.472 | 216.096 | 0,14% | Azioni |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $12.137.385 | 214.859 | 0,14% | Azioni |
| GLENMEDE TRUST CO NA | $11.782.055 | 205.908 | 0,14% | Azioni |
| Retirement Systems of Alabama | $11.438.907 | 199.911 | 0,13% | Azioni |
| IEQ CAPITAL, LLC | $11.328.874 | 197.988 | 0,13% | Azioni |
| Mariner, LLC | $11.021.160 | 192.607 | 0,13% | Azioni |
| Monaco Asset Management SAM | $10.582.095 | 184.937 | 0,12% | Azioni |
| Engineers Gate Manager LP | $10.393.841 | 181.647 | 0,12% | Azioni |
| VANGUARD ASSET MANAGEMENT, Ltd | $9.840.867 | 171.983 | 0,11% | Azioni |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $9.713.000 | 169.746 | 0,11% | Azioni |
| RAYMOND JAMES FINANCIAL INC | $9.595.050 | 167.687 | 0,11% | Azioni |
| VAN ECK ASSOCIATES CORP | $9.444.504 | 165.056 | 0,11% | Azioni |
| PEREGRINE CAPITAL MANAGEMENT LLC | $9.310.495 | 162.714 | 0,11% | Azioni |
| CWM, LLC | $9.018.745 | 159.652 | 0,10% | Azioni |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $9.015.469 | 157.558 | 0,10% | Azioni |
| BARCLAYS PLC | $8.865.839 | 154.943 | 0,10% | Azioni |
| Legal & General Group Plc | $8.722.675 | 152.441 | 0,10% | Azioni |
Insider aziendali 48 insider · 19 dirigenti · 29 direttori
| Insider | Ruolo | Ultima attività | Azioni possedute | Acquisti 12m | Vendite 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Alexander Hardy | Chief Executive Officer | 17 Marzo 2025 A | 175.583 | 0 | 0 | $0 |
| Louis Drapeau | Chief Executive Officer | 02 Maggio 2005 A | 14.934 | 0 | 0 | $0 |
| Fredric D Price | Chief Executive Officer | 06 Maggio 2004 P | 79.285 | 0 | 0 | $0 |
| Brian Mueller | EVP, Chief Financial Officer | 17 Marzo 2025 A | 99.781 | 0 | 0 | $0 |
| Daniel K Spiegelman | EVP, Chief Financial Officer | 22 Giugno 2018 S | 51.070 | 0 | 0 | $0 |
| Jeffrey H Cooper | SVP, Chief Financial Officer | 14 Maggio 2012 M | 41.089 | 0 | 0 | $0 |
| Henry J Fuchs | President, Worldwide R&D | 13 Settembre 2024 F | 185.074 | 0 | 0 | $0 |
| Cristin Hubbard | EVP, Chief Commercial Officer | 20 Maggio 2025 F | 30.545 | 0 | 0 | $0 |
| Erin Burkhart | GVP, Chief Accounting Officer | 20 Maggio 2025 S | 14.173 | 0 | 0 | $0 |
| Gregory R Friberg | EVP, Chief R&D Officer | 17 Marzo 2025 A | 46.810 | 0 | 0 | $0 |
| Charles Greg Guyer | EVP, Chief Technical Officer | 17 Marzo 2025 A | 80.838 | 0 | 0 | $0 |
| George Eric Davis | EVP, Chief Legal Officer | 17 Marzo 2025 A | 82.915 | 0 | 0 | $0 |
| Jeffrey Robert Ajer | EVP, Chief Commercial Officer | 02 Maggio 2024 S | 66.767 | 0 | 0 | $0 |
| Robert Baffi | EVP, Technical Operations | 22 Giugno 2018 M | 83.276 | 0 | 0 | $0 |
| Steve Aselage | EVP, Chief Business Officer | 02 Luglio 2012 M | 59.030 | 0 | 0 | $0 |
| Emil D Kakkis | Chief Medical Officer | 02 Marzo 2009 M | 39.621 | 0 | 0 | $0 |
| Stuart J Swiedler | SVP, Clinical Affairs | 07 Luglio 2008 A | 12.000 | 0 | 0 | $0 |
| Christopher M Starr | SVP, Chief Scientific Officer | 01 Dicembre 2005 M | 295.176 | 0 | 0 | $0 |
| Jeffrey Landau | SVP, Administration | 31 Ottobre 2004 A | 2.740 | 0 | 0 | $0 |
| Elizabeth M Anderson | Direttore | 02 Giugno 2026 A | 41.940 | 0 | 0 | $0 |
| Barbara W. Bodem | Direttore | 02 Giugno 2026 A | 21.045 | 0 | 0 | $0 |
| Maykin Ho | Direttore | 02 Giugno 2026 A | 35.500 | 0 | 0 | $0 |
| Mark J Enyedy | Direttore | 02 Giugno 2026 A | 21.040 | 0 | 0 | $0 |
| Athena Countouriotis | Direttore | 02 Giugno 2026 A | 21.040 | 0 | 0 | $0 |
| Robert J. Hombach | Direttore | 02 Giugno 2026 A | 49.360 | 0 | 0 | $0 |
| Timothy P Walbert | Direttore | 02 Giugno 2026 A | 17.270 | 0 | 0 | $0 |
| Ian T Clark | Direttore | 02 Giugno 2026 A | 14.490 | 0 | 0 | $0 |
| Willard H Dere | Direttore | 02 Giugno 2026 A | 46.440 | 0 | 0 | $0 |
| Richard A Meier | Direttore | 20 Maggio 2025 A | 127.426 | 0 | 0 | $0 |
| Elaine J Heron | Direttore | 03 Giugno 2024 M | 97.720 | 0 | 0 | $0 |
| David E I Pyott | Direttore | 21 Maggio 2024 A | 49.750 | 0 | 0 | $0 |
| Jean Jacques Bienaime | Direttore | 20 Maggio 2024 F | 473.792 | 0 | 0 | $0 |
| Dennis Slamon | Direttore | 18 Marzo 2024 M | 31.299 | 0 | 0 | $0 |
| Mark J Alles | Direttore | 23 Maggio 2023 A | 15.095 | 0 | 0 | $0 |
| Bryan V Lawlis | Direttore | 23 Maggio 2023 A | 33.140 | 0 | 0 | $0 |
| Michael G Grey | Direttore | 05 Giugno 2018 A | 34.110 | 0 | 0 | $0 |
| Alan Lewis | Direttore | 05 Giugno 2018 A | 25.360 | 0 | 0 | $0 |
| Kathryn E Falberg | Direttore | 15 Luglio 2016 A | 2.640 | 0 | 0 | $0 |
| William D Young | Direttore | 10 Giugno 2015 A | 11.875 | 0 | 0 | $0 |
| Kenneth Bate | Direttore | 10 Giugno 2015 A | 11.875 | 0 | 0 | $0 |
| Pierre Lapalme | Direttore | 10 Giugno 2015 A | 31.250 | 0 | 0 | $0 |
| Joseph Klein III | Direttore | 08 Marzo 2010 S | 35.000 | 0 | 0 | $0 |
| Franz L Cristiani | Direttore | 14 Giugno 2006 A | — | 0 | 0 | $0 |
| Erich Sager | Direttore | 24 Febbraio 2006 M | 3.309 | 0 | 0 | $0 |
| Gwynn Williams | Direttore | 30 Novembre 2004 A | 812.565 | 0 | 0 | $0 |
| John Urquhart | Direttore | 28 Luglio 2004 A | — | 0 | 0 | $0 |
| BIOMARIN PHARMACEUTICAL INC | Proprietario del 10% | 08 Dicembre 2012 J | 6.666.667 | 0 | 0 | $0 |
| Mark Wood | — | 22 Maggio 2013 M | 20.277 | 0 | 0 | $0 |
Insider dai depositi SEC Modulo 3/4/5; netto = solo acquisti/vendite di mercato
Attivisti e proprietari del 5%+ 4 partecipazioni
Investitori che hanno depositato SEC Schedule 13D — proprietà effettiva superiore al 5% con l'intento di influenzare l'emittente (partecipazioni attiviste, campagne per il consiglio di amministrazione, M&A). Ogni riga mostra lo stato più recente noto della posizione di quel depositante.
| Depositante | Depositato | Partecipazione | Stato | Scopo | Deposito |
|---|---|---|---|---|---|
| BioMarin Pharmaceutical Inc., BioMarin Falcons B.V., BioMarin Giants B.V. ×5 depositi | 02 Febbraio 2015 | — | Deposito iniziale | — | SEC |
| Millenco LLC, Integrated Core Strategies (US) LLC, Catapult Partners, Ltd., Catapult Capital Management LLC, Millennium International Management LP, Millennium International Management GP LLC, Millennium Management LLC, Israel A. Englander ×2 depositi | 31 Luglio 2009 | — | Deposito iniziale | — | SEC |
| 06 Giugno 2005 | — | Deposito iniziale | Campagna per il consiglio di amministrazione | SEC | |
| OrbiMed Advisors LLC, OrbiMed Capital LLC, Samuel D. Isaly, Richard B. Brewer, Joseph Klein, III ×2 depositi | 06 Maggio 2005 | — | Deposito iniziale | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Proprietà ETF Posseduti da 115 ETF
Il peso riflette solo le partecipazioni azionarie dirette (N-PORT); fondi a leva o basati su derivati possono detenere ulteriore esposizione swap non mostrata.
| Fondo | Peso | Unità | Aggiornato al | Fonte |
|---|---|---|---|---|
| GNOM · Global X Funds | 4,09% | 39.792 NS | 31 Maggio 2026 | N-PORT |
| PBE · Invesco Exchange-Traded Fund Trust | 2,95% | 173.298 SH | 21 Agosto 2026 | Giornaliero |
| FBT · First Trust Exchange-Traded Fund | 2,83% | 1.391.830 NS | 30 Giugno 2026 | N-PORT |
| BBP · ETFis Series Trust I | 1,61% | 17.750 NS | 30 Aprile 2026 | N-PORT |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1,27% | 12.555 NS | 30 Aprile 2026 | N-PORT |
| SRHQ · Elevation Series Trust | 1,14% | 40.919 NS | 30 Aprile 2026 | N-PORT |
| RNIN · EA Series Trust | 1,12% | 31.743 NS | 30 Aprile 2026 | N-PORT |
| FTXH · First Trust Exchange-Traded Fund VI | 1,11% | 7.061 NS | 30 Giugno 2026 | N-PORT |
| IBB · iShares Trust | 0,91% | 1.422.957 SH | 21 Agosto 2026 | Giornaliero |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,84% | 11.352 SH | 21 Agosto 2026 | Giornaliero |
| LABU · Direxion Shares ETF Trust | 0,84% | 80.485 NS | 30 Aprile 2026 | N-PORT |
| FXH · First Trust Exchange-Traded AlphaDE… | 0,83% | 133.988 NS | 30 Aprile 2026 | N-PORT |
| LSEQ · Harbor ETF Trust | 0,69% | 1.977 NS | 30 Aprile 2026 | N-PORT |
| AFMC · First Trust Exchange-Traded Fund VI… | 0,64% | 18.230 NS | 31 Maggio 2026 | N-PORT |
| BIB · ProShares Trust | 0,55% | 7.110 NS | 31 Maggio 2026 | N-PORT |
| TMFX · RBB Fund, Inc. | 0,54% | 3.021 NS | 31 Maggio 2026 | N-PORT |
| SYZ · Lazard Active ETF Trust | 0,52% | 6.190 NS | 30 Giugno 2026 | N-PORT |
| ABCS · EA Series Trust | 0,48% | 948 NS | 29 Maggio 2026 | N-PORT |
| MIDE · DBX ETF Trust | 0,44% | 259 NS | 29 Maggio 2026 | N-PORT |
| IQSM · New York Life Investments ETF Trust | 0,43% | 24.857 NS | 30 Aprile 2026 | N-PORT |
| QVMM · Invesco Exchange-Traded Fund Trust … | 0,41% | 26.193 SH | 21 Agosto 2026 | Giornaliero |
| IVOG · VANGUARD ADMIRAL FUNDS | 0,33% | 108.709 SH | 19 Agosto 2026 | Giornaliero |
| PTMC · Pacer Funds Trust | 0,30% | 22.042 NS | 30 Aprile 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0,30% | 2.559.860 SH | 19 Agosto 2026 | Giornaliero |
| IVOO · VANGUARD ADMIRAL FUNDS | 0,30% | 312.378 SH | 19 Agosto 2026 | Giornaliero |
| DFSV · Dimensional ETF Trust | 0,29% | 400.897 NS | 30 Aprile 2026 | N-PORT |
| BKMC · BNY Mellon ETF Trust | 0,28% | 31.691 NS | 30 Aprile 2026 | N-PORT |
| IVOV · VANGUARD ADMIRAL FUNDS | 0,27% | 71.381 SH | 19 Agosto 2026 | Giornaliero |
| ISCV · iShares Trust | 0,27% | 27.848 SH | 21 Agosto 2026 | Giornaliero |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,25% | 24.275 NS | 30 Aprile 2026 | N-PORT |
| MVV · ProShares Trust | 0,24% | 6.639 NS | 31 Maggio 2026 | N-PORT |
| JIII · Janus Detroit Street Trust | 0,22% | 6.823 NS | 30 Aprile 2026 | N-PORT |
| MIDU · Direxion Shares ETF Trust | 0,21% | 3.182 NS | 30 Aprile 2026 | N-PORT |
| BBMC · J.P. Morgan Exchange-Traded Fund Tr… | 0,21% | 77.243 NS | 30 Aprile 2026 | N-PORT |
| SCHM · SCHWAB STRATEGIC TRUST | 0,20% | 518.955 NS | 31 Maggio 2026 | N-PORT |
| ISCB · iShares Trust | 0,20% | 8.655 SH | 21 Agosto 2026 | Giornaliero |
| IYH · iShares Trust | 0,20% | 114.252 SH | 21 Agosto 2026 | Giornaliero |
| SMMD · iShares Trust | 0,17% | 98.032 SH | 21 Agosto 2026 | Giornaliero |
| UMDD · ProShares Trust | 0,17% | 927 NS | 31 Maggio 2026 | N-PORT |
| RWK · Invesco Exchange-Traded Fund Trust … | 0,16% | 31.608 SH | 21 Agosto 2026 | Giornaliero |
| VFMF · VANGUARD WELLINGTON FUND | 0,16% | 19.998 SH | 19 Agosto 2026 | Giornaliero |
| FHLC · FIDELITY COVINGTON TRUST | 0,16% | 84.082 NS | 30 Aprile 2026 | N-PORT |
| FNDA · SCHWAB STRATEGIC TRUST | 0,16% | 245.186 NS | 31 Maggio 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,15% | 534.462 SH | 19 Agosto 2026 | Giornaliero |
| ISCG · iShares Trust | 0,14% | 21.297 SH | 21 Agosto 2026 | Giornaliero |
| VFVA · VANGUARD WELLINGTON FUND | 0,14% | 20.990 SH | 19 Agosto 2026 | Giornaliero |
| DFAS · Dimensional ETF Trust | 0,14% | 361.639 NS | 30 Aprile 2026 | N-PORT |
| ESML · iShares Trust | 0,13% | 55.771 SH | 21 Agosto 2026 | Giornaliero |
| VB · VANGUARD INDEX FUNDS | 0,13% | 4.433.137 SH | 19 Agosto 2026 | Giornaliero |
| IWS · iShares Trust | 0,12% | 288.341 SH | 21 Agosto 2026 | Giornaliero |